作为用于治疗炎症和自身免疫性疾病的NIK抑制剂的吡咯烷酮衍生物
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Feb 14;15(3):322-323. doi: 10.1021/acsmedchemlett.4c00044. eCollection 2024 Mar 14.
Abstract
Provided herein are novel pyrrolidinone derivatives as NIK inhibitors, pharmaceutical compositions, use of such compounds in treating inflammatory and autoimmune diseases, and processes for preparing such compounds.
摘要
本文提供了作为NIK抑制剂的新型吡咯烷酮衍生物、药物组合物、此类化合物在治疗炎症和自身免疫性疾病中的用途以及制备此类化合物的方法。
相似文献
1
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2024 Feb 14;15(3):322-323. doi: 10.1021/acsmedchemlett.4c00044. eCollection 2024 Mar 14.
2
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Apr 23;15(5):581-582. doi: 10.1021/acsmedchemlett.4c00169. eCollection 2024 May 9.
3
Novel Pyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.
ACS Med Chem Lett. 2024 Nov 14;15(12):2093-2094. doi: 10.1021/acsmedchemlett.4c00536. eCollection 2024 Dec 12.
4
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Jan 26;15(2):177-178. doi: 10.1021/acsmedchemlett.4c00011. eCollection 2024 Feb 8.
5
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.
ACS Med Chem Lett. 2023 Apr 25;14(5):553-554. doi: 10.1021/acsmedchemlett.3c00139. eCollection 2023 May 11.
6
TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Feb 6;15(3):320-321. doi: 10.1021/acsmedchemlett.4c00024. eCollection 2024 Mar 14.
7
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 May 16;15(6):769-770. doi: 10.1021/acsmedchemlett.4c00196. eCollection 2024 Jun 13.
8
Novel Pyrido[3,2-]pyrimidines as HPK1 Inhibitors for Treating Cancer and Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2023 Nov 27;14(12):1627-1628. doi: 10.1021/acsmedchemlett.3c00506. eCollection 2023 Dec 14.
9
Novel Tetrahydropyrido[3,4-]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases.
ACS Med Chem Lett. 2024 Jan 31;15(3):318-319. doi: 10.1021/acsmedchemlett.4c00023. eCollection 2024 Mar 14.
10
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Dec 9;16(1):8-9. doi: 10.1021/acsmedchemlett.4c00566. eCollection 2025 Jan 9.
引用本文的文献
1
evaluation of potential breast cancer receptor antagonists from GC-MS and HPLC identified compounds in extracts.
RSC Adv. 2024 Aug 9;14(33):23744-23771. doi: 10.1039/d4ra03832k. eCollection 2024 Jul 26.
2
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Apr 23;15(5):581-582. doi: 10.1021/acsmedchemlett.4c00169. eCollection 2024 May 9.
本文引用的文献
1
The role and therapeutic potential of nuclear factor κB (NF-κB) in ischemic stroke.
Biomed Pharmacother. 2024 Feb;171:116140. doi: 10.1016/j.biopha.2024.116140. Epub 2024 Jan 11.
2
NF-κB and Related Autoimmune and Autoinflammatory Diseases.
Rheum Dis Clin North Am. 2023 Nov;49(4):805-823. doi: 10.1016/j.rdc.2023.06.008. Epub 2023 Aug 1.
3
The crosstalk between Nrf2 and NF-κB pathways in coronary artery disease: Can it be regulated by SIRT6?
Life Sci. 2023 Oct 1;330:122007. doi: 10.1016/j.lfs.2023.122007. Epub 2023 Aug 5.
4
Negative regulatory NLRs mitigate inflammation via NF-κB pathway signaling in inflammatory bowel disease.
Biomed J. 2023 Oct;46(5):100616. doi: 10.1016/j.bj.2023.100616. Epub 2023 Jun 14.
Zotero 插件